ERJ
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Order Full text via Infotrieve
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wells, A.
Right arrow Articles by du Bois, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wells, A.
Right arrow Articles by du Bois, R.
Eur Respir J 1993; 6: 797-802
Copyright © ERS Journals Ltd 1993

Original Articles

Clearance of inhaled 99mTc-DTPA predicts the clinical course of fibrosing alveolitis

AU Wells, DM Hansell, NK Harrison, R Lawrence, CM Black, and RM du Bois

The aim of this study was to determine whether the speed of technetium-labelled diethylene-triamine-pentacetate (99mTc-DTPA) clearance from the lung is predictive of disease progression in fibrosing alveolitis, as judged by changes in respiratory function tests. 82 nonsmoking patients with fibrosing alveolitis were studied (progressive systemic sclerosis, n = 53; lone cryptogenic fibrosing alveolitis, n = 29). Normal 99mTc-DTPA clearance at initial measurement predicted stable disease; rapid 99mTc-DTPA clearance identified patients at risk of deterioration. Repeat measurement of clearance, approximately 12 months later, enabled the definition of a subgroup at higher risk, with persistently abnormal 99mTc-DTPA clearance, and a smaller subgroup in whom reversion of clearance to normal was associated with a sustained improvement in respiratory function indices. These findings were not attributable to differences in treatment between subgroups. We conclude that the speed of 99mTc-DTPA clearance discriminates between stable and progressive disease in fibrosing alveolitis.


This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
R. M. du Bois
State of the Art. Mechanisms of Scleroderma-induced Lung Disease
Proceedings of the ATS, August 15, 2007; 4(5): 434 - 438.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
E. Bodolay, Z. Szekanecz, K. Devenyi, L. Galuska, I. Csipo, J. Vegh, I. Garai, and G. Szegedi
Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD)
Rheumatology, May 1, 2005; 44(5): 656 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
K. Suga, Y. Yuan, N. Ogasawara, T. Tsukuda, and N. Matsunaga
Altered Clearance of Gadolinium Diethylenetriaminepentaacetic Acid Aerosol from Bleomycin-injured Dog Lungs: Initial Observations
Am. J. Respir. Crit. Care Med., June 15, 2003; 167(12): 1704 - 1710.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
V. V. Kaushik, M. P. Lynch, J. K. Dawson, C. A. Kelly, V. Saravanan, D. Shovlin, and B. A. Rajasekaran
Tc-DTPA clearance and rheumatoid arthritis-associated fibrosing alveolitis
Rheumatology, June 1, 2002; 41(6): 712 - 713.
[Full Text] [PDF]

Home page
 ThoraxHome page
N Mogulkoc, M H Brutsche, P W Bishop, B Murby, M S Greaves, A W Horrocks, M Wilson, C McCullough, M Prescott, and J J Egan
Pulmonary 99mTc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP)
Thorax, December 1, 2001; 56(12): 916 - 923.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
B. A. Rajasekaran, D. Shovlin, P. Lord, and C. A. Kelly
Interstitial lung disease in patients with rheumatoid arthritis: a comparison with cryptogenic fibrosing alveolitis
Rheumatology, September 1, 2001; 40(9): 1022 - 1025.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
R.M. du Bois and A.U. Wells
Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis
Eur. Respir. J., July 1, 2001; 18(32_suppl): 43S - 55s.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
S. C Bourke and H. Clague
Review of cryptogenic fibrosing alveolitis, including current treatment guidelines
Postgrad. Med. J., October 1, 2000; 76(900): 618 - 624.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
H. TAKAHASHI, Y. KUROKI, H. TANAKA, T. SAITO, K. KUROKAWA, H. CHIBA, A. SAGAWA, H. NAGAE, and S. ABE
Serum Levels of Surfactant Proteins A and D Are Useful Biomarkers for Interstitial Lung Disease in Patients with Progressive Systemic Sclerosis
Am. J. Respir. Crit. Care Med., July 1, 2000; 162(1): 258 - 263.
[Abstract] [Full Text]

Home page
 ThoraxHome page
A. Wells
Clinical usefulness of high resolution computed tomography in cryptogenic fibrosing alveolitis
Thorax, December 1, 1998; 53(12): 1080 - 1087.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. GABBAY, R. TARALA, R. WILL, G. CARROLL, B. ADLER, D. CAMERON, and F. R. LAKE
Interstitial Lung Disease in Recent Onset Rheumatoid Arthritis
Am. J. Respir. Crit. Care Med., July 1, 1997; 156(2): 528 - 535.
[Abstract] [Full Text]

Home page
 BMJHome page
R M D. Bois
Fortnightly Review: Diffuse lung disease: an approach to management
BMJ, July 16, 1994; 309(6948): 175 - 175.
[Full Text]

Home page
 ThoraxHome page
B. T. SOCIETY and S. O. C. COMMITTEE
The Diagnosis, Assessment and Treatment of Diffuse Parenchymal Lung Disease in Adults---British Thoracic Society recommendations
Thorax, April 1, 1990; 54(90001): 1S - 28.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by the European Respiratory Society.